Hepatocellular carcinoma (HCC), one of the most dangerous malignancies with an increasing incidence and a high mortality rate, represents a major international health problem. HCC progression is known to involve genome-wide alteration of epigenetic modifications, leading to aberrant gene expression patterns. The activity of CYP2C19, an important member of the cytochrome P450 superfamily, was reported to be compromised in HCC, but the underlying mechanism remains unclear. To understand whether epigenetic modification in HCC is associated with a change in CYP2C19 activity, we evaluated the expression levels of CYP2C19 and its transcription factors by quantitative real-time polymerase chain reaction using mRNA extracted from both primary hepatocytes and paired tumor versus nontumor liver tissues of patients infected with hepatitis B virus (HBV). DNA methylation was examined by bisulfite sequencing and methylation-specific polymerase chain reaction. Our results indicated that CYP2C19 could be regulated by e-box methylation of the constitutive androstane receptor (CAR). Decreased CYP2C19 expression in tumorous tissues of HBV-infected patients with HCC was highly correlated with suppressed expression and promoter hypermethylation of CAR. Our study demonstrates that aberrant CAR methylation is involved in CYP2C19 regulation in HBV-related HCC and may play a role in liver tumorigenesis.
Introduction
Although tremendous efforts have been made in the fight against hepatocellular carcinoma (HCC), HCC is the fifth most prevalent cancer worldwide and is currently the third leading cause of cancer mortality (Jemal et al., 2011) . Hepatitis B virus (HBV) infection, hepatitis C virus infection, and alcohol abuse are the main causes of HCC, and HBV infection accounts for 60% of HCC in the Chinese population (Yang et al., 2014) . A recent World Health Organization report estimates that 90 million people in China (almost 7% of the population) are chronically infected with HBV (Liu et al., 2016) .
HCC progression was traditionally considered a gradual multistep process of normal cells evolving into tumor cells caused by mutations that led to altered hepatocellular phenotypes (Thorgeirsson and Grisham, 2002; Lessel et al., 2014) . However, evidence accumulated in the past few decades suggests that altered epigenetic modifications also play a pivotal role in HCC development (Nishida and Goel, 2011) . DNA methylation, which refers to the addition of a methyl group to the cytosine within a CpG dinucleotide, is the most intensively studied epigenetic mechanism in mammals. The cancerous tissues in HCC are reported to possess a unique methylation landscape that differs from adjacent tissues. In HCC, the methylome feature is roughly characterized by global hypomethylation and gene-specific DNA hypermethylation, which contribute to genomic instability and inactivation of tumor-suppressor genes, respectively (Herceg and Paliwal, 2011) . Since advanced HCC is highly lethal and incurable, there is an urgent need to understand the tumorigenesis process and to search for new diagnostic biomarkers and novel therapeutic targets.
CYP2C19 is one of the most important members of the cytochrome P450 (P450) superfamily and is responsible for the metabolism of a variety of clinically important drugs such as mephenytoin, diazepam, and some barbitals (Griskevicius et al., 2003) . The genetic polymorphisms of CYP2C19 have been well studied. Individuals can be classified as extensive metabolizers, intermediate metabolizers, poor metabolizers, and ultra-rapid metabolizers based on the catalytic capacity of the enzyme, which largely depends on the different alleles individuals carry (Uppugunduri et al., 2012) . The regulatory mechanism of CYP2C19 is currently characterized by several nuclear receptors and transcription factors, including the constitutive androstane receptor (CAR), pregnane X receptor, glucocorticoid receptor a, and hepatocyte nuclear factor-3g. Of these, CAR seems to play a central role and has a strong association with the basal expression level of CYP2C19 (Wortham et al., 2007) . It has been predicted that epigenetics might also play a role in CYP2C19 regulation, and some CpG sites exist in the 59-flanking region of the CYP2C19 gene but their functional importance remains to be further elucidated (Ingelman-Sundberg et al., 2007) .
CYP2C19 expression is reported to be decreased in advanced cancer, including breast cancer, lung cancer, and HCC, which is also accompanied by compromised enzymatic activity (Tsunedomi et al., 2005; Helsby et al., 2008) . Despite researchers' extensive efforts to investigate the underlying mechanism over the past years, altered expression of CYP2C19 in HCC does not appear to be fully accounted for by known polymorphisms, inflammatory factors, or growth hormones (Helsby et al., 2008) . This study aimed to investigate the possible epigenetic mechanism of decreased CYP2C19 expression in HBV-infected patients with HCC. Since CYP2C19 is also important in the disposition of a number of chemotherapeutic agents, including cyclophosphamide, thalidomide, and bortezomib, elucidating the epigenetic modulation of CYP2C19 might also help improve understanding and prediction of chemotherapy outcomes for patients with HCC.
Materials and Methods
Cell Culture and Tissue Samples. HepG2 and human embryonic kidney 293 (HEK293) cells were grown in Dulbecco's modified Eagle's medium (Life Technologies, Carlsbad, CA), supplemented with 10% fetal bovine serum (Life Technologies) and 1% penicillin-streptomycin (Life Technologies), at 37°C with 5% CO 2 . Human kidney-2 (HK2) cells were grown in Dulbecco's modified Eagle's medium/F-12 medium (Life Technologies) supplemented with 18% fetal bovine serum at 37°C with 5% CO. Cryopreserved primary hepatocytes (Research Institute for Liver Disease, Shanghai, China) from one male donor and one female donor (Supplemental Table 1 ) were plated in InVitroGRO CP medium (BioreclamationIVT, Baltimore, MD) at 37°C with 5% CO 2 before drug incubation. Two replicates were conducted for each donor.
Thirty pairs of tumorous and adjacent liver tissues were obtained from fresh surgical specimens of HBV-infected patients with HCC (HBV DNA . 1000 copies/ml or positive hepatitis B surface antigen and hepatitis B core antibody test results) and were then stored in liquid nitrogen before use. The selected patients did not receive any radiotherapy or chemotherapy previously. Tissues were obtained from Zhejiang Cancer Hospital (Hangzhou, China). Information on liver species is provided in Supplemental Table 2. The research protocol was carried out in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Zhejiang Cancer Hospital.
Treatment of Primary Hepatocytes with 5-Aza-29-Deoxycytidine. Primary hepatocytes were seeded at a density of 5 Â 10 5 cells/ml in collagen-coated, sixwell plates (Life Technologies) with InVitroGRO CP medium. The medium was changed the next day to remove the unattached cells. After 24 hours of plating, drug incubation started with 1 mM and 2 mM 5-aza-29-deoxycytidine (5-aza-dC; Sigma-Aldrich, St. Louis, MO) (Christman, 2002) in InVitroGRO HI medium supplemented with 25 ng/ml epidermal growth factor (Sigma-Aldrich) to stimulate proliferation. The control group was treated with 0.1% dimethylsulfoxide. The medium was changed every other day. Cells were harvested after 5 days treatment for DNA and RNA isolation.
Semiquantitative Real-Time Polymerase Chain Reaction. mRNA was extracted from tissue samples and cultured cells using the RNeasy Mini Kit (Qiagen, Valencia, CA). Five-hundred nanograms of mRNA was used in a reversetranscribed polymerase chain reaction (PCR) performed with the PrimeScript RT Reagent Kit (Takara, Tokyo, Japan). Quantitative real-time PCR was then performed using SYBR Premix Ex Taq II (Takara) and the StepOnePlus system (Applied Biosystems, Foster City, CA). Primers for quantitative real-time PCR are listed in Table 1 . Relative quantitation of gene expression was calculated with the 2 2DDCt method as described previously (Schmittgen and Livak, 2008) .
DNA Methylation Analysis. Genomic DNA from tissue samples or cells was isolated using the DNeasy Blood and Tissue Kit (Qiagen). DNA was considered qualified with a ratio of absorbance at 260 nm and 280 nm (A260/A280) between 1.7 and 1.9. Samples were stored in elution buffer at 280°C before use.
Sodium bisulfite modification of DNA samples was conducted using an EZ DNA Methylation-Gold Kit (Zymo, Orange, CA). The location of all CpG sequences examined in this study is shown in Fig. 1 . PCR amplification was done with rTaq polymerase (Takara) in a 50-ml reaction mixture with 2 ml modified DNA as the template. PCR amplification started with 10 cycles of touchdown PCR of 30 seconds at 94°C, 30 seconds at 60°C to 55°C (20.5°C per cycle), and then 45 seconds at 72°C and 30 cycles of 30 seconds at 94°C, 30 seconds at 55°C, and 45 seconds at 72°C, followed by an extension of 10 minutes at 72°C. Amplicons were then purified and subcloned into pMD18-T vector (Takara) according to the manufacturer's instructions. Ligation products were transformed into Escherichia coli DH5a cells and 10-15 random colonies with recombinant plasmids were subjected to Sanger sequencing (Sangon, Shanghai, China).
Methylation-specific PCR was also conducted using the modified DNA as a template. The following touchdown PCR program was applied: 10 cycles of touchdown PCR of 30 seconds at 94°C, 30 seconds at 58°C to 53°C (20.5°C per cycle), 20 seconds at 72°C and 25 cycles of 30 seconds at 94°C, 30 seconds at 53°C, and 20 seconds at 72°C, followed by a final extension of 10 minutes at 72°C. Ten-microliter PCR products were shown on 2% agarose gel containing ethidium bromide. Primers for methylation analysis are listed in Table 2 .
Plasmid Construction. pCpGL-CYP2C19 (21977 to +64), pCpGL-CAR-CGI (21446 to +1971), pCpGL-CAR-2E (+175 to +1971), and pCpGL-CAR-1E (+384 to +1971) were constructed with a CpG-free luciferase reporter vector named pCpGL-basic (a kind gift from Prof. Michael Rehli, University Hospital, Regensburg, Germany) ( Fig. 2A ) (Klug and Rehli, 2006) . pCpGL-CYP2C19 contains an approximately 2.0-kb sequence of the 59-flanking promoter region of CYP2C19. pCpGL-CAR-CGI contains an approximately 3.5-kb sequence with a 
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CpG island on the 59-flanking region and both e-box binding sites close to the transcription start site and translation start site of CAR, respectively. In pCpGL-CAR-2E, the CpG island region was deleted from the sequence of pCpGL-CAR-CGI; in pCpGL-CAR-1E, another approximately 200-bp sequence that contains the first e-box binding site was deleted. In addition, a full-length CAR coding DNA sequence amplified from mRNA (primers CDS-F/R) was ligated with the 59-flanking region as well as the untranslated exon 1 and intron 1 (amplified by primers Flanking-F/R) by overlap PCR. The approximately 3-kb ligated fragment was then inserted into a CpG-free expression vector, pCpGfree-mcs (Fig. 2B ) (InvivoGen, San Diego, CA), to construct pCpGfree-CAR. Primers used for plasmid construction are listed in Table 3 . All constructs were confirmed by Sanger sequencing (Sangon).
In Vitro Methylation of Plasmid DNA. Plasmids were methylated using M.SssI (New England Biolabs, Beverly, MA) according to the manufacturer's instructions. Two micrograms of plasmid DNA was incubated in a 40-ml volume with 2 ml (4 U/ml) SssI and 160 mM S-adenosyl methionine at 37°C for 6 hours. The control group of plasmids also underwent the same incubation but in the absence of SssI. The reaction was stopped by heating at 65°C for 20 minutes. Both the methylated group and the control group of plasmid DNA were purified with the Axygen PCR Clean-Up Kit (Axygen, Hangzhou, China).
Transient Transfection Assay. HepG2, HEK293, or HK2 cells were seeded in 24-well plates at a density of 2.5 Â 10 5 /ml. The transient transfection was carried out using Lipofectamine2000 (Life Technologies) when cells reached 70%-80% confluence. Reporter plasmids and expression plasmids were transfected at 500 ng and 250 ng per well, respectively, with 50 ng pRL-TK per well as the internal control. Medium was refreshed 6 hours after transfection. Luciferase activity was assessed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) 48 hours after transfection.
Statistical Analysis. Quantitative PCR results are shown as 2 2DDCt using glyceraldehyde 3-phosphate dehydrogenase as a housekeeping gene. The methylation percentage of bisulfite sequencing polymerase chain reaction (BSP) analysis was calculated as the number of methylated cytosines divided by the total number of cytosines on the CpG site in all amplicons. The methylation percentage of a sequence was determined as the average percentage of all CpG sites within this region. Comparisons of the methylation percentage and mRNA expression between groups were analyzed by a paired t test using GraphPad Prism software (version 5.0; GraphPad Software Inc., San Diego, CA). The Pearson correlation was used to determine the correlation between CYP2C19 and CAR expression. Differences or correlations were considered statistically significant at P , 0.05, P , 0.01, and P , 0.001.
Results
Increased CYP2C19 and CAR mRNA in Primary Hepatocytes after 5-Aza-dC Treatment. To determine whether DNA methylation is a potential mechanism of CYP2C19 regulation in the liver, a DNA methyltransferase inhibitor (5-aza-dC) was applied to the primary cultures of human hepatocytes. Quantitative real-time PCR analysis revealed an increase in CYP2C19 and CAR expression in a dose-dependent manner, whereas other transcription factors were not significantly affected (Fig. 3) . To investigate whether demethylation led to the elevated expression level of CYP2C19 and CAR in primary hepatocytes, BSP was performed on the promoter regions as shown in Fig. 1 . BSP results revealed a moderate methylation frequency on the CpG-poor promoter of CYP2C19 (52.5%) as well as the two e-box binding sites on CAR (50% and 47.5%). After 5-aza-dC treatment, the methylation frequency of these three regions decreased to 38.3%, 13.3%, and 42.5%, respectively (Fig. 4, A-C) . The CpG island on the CAR promoter, which was highly methylated (92.5%), also showed decreased methylation frequency (72.5%) after exposure to 5-aza-dC (Fig. 4D) . BSP results showed an overall decreased DNA methylation level on the promoter of CYP2C19 and CAR after 5-aza-dC treatment. These results suggest that DNA methylation is a regulatory mechanism of CYP2C19 in the liver and CAR might also be involved. at ASPET Journals on November 6, 2017 dmd.aspetjournals.org
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Decreased mRNA Expression of CYP2C19 and CAR in Tumorous Tissues. Expression of CYP2C19 and CAR in tumorous and adjacent tissues is shown as grouped column scatter plots with means 6 S.E. in Fig. 5A . The average expression of CYP2C19 in tumorous tissues (0.39 6 0.20) was significantly decreased compared with the normal tissues (2.4 6 0.40, P , 0.001). In addition, the average expression of CAR also decreased significantly (0.40 6 0.085 versus 1.40 6 0.15, P , 0.001).
Alterations of the expression levels of CYP2C19 and CAR were correlated, with a Pearson correlation coefficient of 0.31 (R 2 = 0.09, P , 0.05) (Fig. 5C) .
Elevated Methylation Level of CpG Sites on the CAR Promoter in Tumorous Tissues. BSP analysis of segment 5 on CAR was performed using DNA from paired tumor and adjacent tissue samples. Representative BSP results are shown in Fig. 6A and the corresponding dmd.aspetjournals.org relative mRNA expression is shown in Fig. 5B . Clearly, in BSP analysis, CpG 3, CpG 5, and CpG 6 in segment 5 around the transcription start site of CAR had a higher methylated status in tumorous tissue compared with adjacent tissue. Among these three sites, CpG 3 is a potential e-box binding site, whereas CpG 5 and CpG 6 are two adjacent CpG sites 121 bp downstream of CpG 3. In addition, methylation-specific PCR within segment 5 also revealed a higher methylation level in tumorous tissues (Fig. 6B) . Interestingly, in the case of sample 246564, the expression levels of CAR and CYP2C19 were increased while methylation status was decreased in tumorous tissues (Fig. 6A) . No significant methylation difference was detected between tumorous and adjacent tissues in the other segments analyzed using BSP (data not shown).
In Vitro Methylation on the CAR Promoter Leads to Decreased CAR-Mediated CYP2C19 Expression in HepG2 Cells. Results of the dual-luciferase reporter assay showed that the CpG-poor 2-kb promoter of CYP2C19 was not affected by methylation (Fig. 7, A, C, D ) in all tested cell lines, suggesting that these sporadic CpG sites are irrelevant to the methylation mechanism. The unmethylated pCpGL-CAR-CGI was 2.5-fold higher in relative luciferase activity compared with the methylated group in HepG2 cells. This fold change remained after the deletion of the CpG island, as shown by the unmethylated versus methylated pCpGL-CAR-2E (2.2-fold), but was greatly reduced after deletion of the 200-bp fragment containing the e-box binding site near the transcription start site (in the first intron). Our results indicate that this e-box binding site was essential in the methylation-regulating mechanism of CAR, whereas the e-box close to the translation start site was not involved. However, no difference between the methylated and unmethylated groups was found in HK2 or HEK293 cells (Fig. 7, C and D) .
To explore whether the methylation-mediated decrease of CAR could exert an effect on CYP2C19 expression, either methylated or unmethylated pCpGfree-CAR was cotransfected with pCpGL-CYP2C19 in HepG2 cells. A 2.3-fold higher luciferase activity was observed in the unmethylated pCpGfree-CAR group (Fig. 7B) , which further supported the finding that CYP2C19 could be suppressed through hypermethylation caused by a decrease in CAR expression.
Discussion
HBV infection remains a key public health issue in China according to the World Health Organization's 2014 World Cancer Report (Bernard et al., 2014) . HBV-induced hepatocarcinogenesis includes proteomic disruption, viral integrations, and aberrant epigenetic modifications (Ji et al., 2014) . Our study demonstrates that DNA demethylation leads to elevated CAR and CYP2C19 expression in primary hepatocytes. This finding suggests that DNA methylation is a potential mechanism of CAR and CYP2C19 regulation in the liver. This notion is further supported by suppressed expression of CAR and CYP2C19 in Chinese patients with HBV-related HCC.
Since CAR is a member of the nuclear receptor superfamily and is a central modulator of oxidative and conjugative enzymes and transporters that are involved in drug disposition and metabolism, it is conceivable that the suppression of CAR plays an important role in the altered expression of CYP2C19 and possibly other drug metabolism targeting genes. P450s participate in the activation and metabolism of a large number of chemotherapeutic agents such as docetaxel (Shou et al., 1998) and cyclophosphamide (Griskevicius et al., 2003) . Thus, CAR suppression mediated by hypermethylation may lead to disturbance of the drug metabolizing system. Therefore, the methylation status of CAR might serve as a biomarker of altered pharmacokinetics. Indeed, other studies have confirmed that several CAR-regulating P450 genes were also suppressed along with decreased CAR expression in end-stage HCC at ASPET Journals on November 6, 2017 dmd.aspetjournals.org Downloaded from (Chen et al., 2014) , but no significant decrease in CAR and related P450 genes was found in HBV cirrhosis samples. This finding suggests that the sharp decline in expression of these genes might occur when liver cirrhosis evolves into carcinoma. However, our results only offered a Pearson correlation coefficient of 0.31 between CYP2C19 and CAR expression, in contrast with a stronger correlation (0.693) observed in healthy liver samples (Wortham et al., 2007) . Since downregulation of metabolism-related genes is demonstrated to be preferentially linked with HBV-related HCC rather than hepatitis C virus-related HCC (Okabe et al., 2001; Iizuka et al., 2002) , it is possible that the virus itself overlooked. In fact, non-CpG island methylation seems to be more dynamic and therefore more changeable during development or pathogenesis. For example, the CpG-poor LAMB3 promoter was shown to be hypomethylated in primary bladder tumors. In vitro methylation of the promoter can directly lead to transcription silencing (Han et al., 2011) . Furthermore, enhancers (which can reside at variable distances from promoters and are mostly CpG poor) also tend to show variable methylation status. Lempiäinen et al. (2011) demonstrated that long-term activation of CAR in mice can lead to HCC, which is accompanied by a switch in the methylomes. However, whether CAR plays a direct role in human HCC remains controversial. Cancer pathogenesis is a complex process in which multiple genetic and epigenetic factors are regulated abnormally. This complexity poses a formidable challenge to holistic integration of information when the investigation is limited to only a certain gene. Traditionally, epigenetic research on cancer has mostly focused on tumor suppressors or oncogenes. Only in recent years has the necessity of building a comprehensive epigenome map been realized. Compared with the well established Human Genome Project, the International Human Epigenome Consortium was launched recently in 2010 (http:// ihec-epigenomes.org/) and aims to increase understanding of how the epigenome has shaped human populations over generations and how it is responds to the environment. The consortium's goals include generating high-resolution maps of DNA methylation and informative histone modifications and performing a comparative analysis of epigenome maps between healthy and diseased states. It is highly anticipated that advances in the field of epigenetics will shed light on intricate life processes such as tumorigenesis and aging.
